DOCSLIB.ORG

Official Journal L 175

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Official Journal L 175 ISSN 0378-6978 Official Journal L 175 Volume 42 of the European Communities 10 July 1999 English edition Legislation Contents I Acts whose publication is obligatory Commission Regulation (EC) No 1502/1999 of 9 July 1999 establishing the standard import values for determining the entry price of certain fruit and vegetables ........... 1 Commission Regulation (EC) No 1503/1999 of 9 July 1999 on issuing A2 export licences for fruit and vegetables ................................................... 3 Commission Regulation (EC) No 1504/1999 of 9 July 1999 amending Regulation (EC) No 1304/1999 fixing export refunds on fruit and vegetables ......................... 5 Commission Regulation (EC) No 1505/1999 of 9 July 1999 on the issue of import licences for high-quality fresh, chilled or frozen beef and veal ........................ 6 = Commission Regulation (EC) No 1506/1999 of 9 July 1999 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff ............................................ 7 Commission Regulation (EC) No 1507/1999 of 9 July 1999 amending Regulation (EC) No 1667/98 increasing to 439 595 tonnes the quantity of barley held by the Swedish intervention agency for which a standing invitation to tender for export has been opened ........................................................................ 23 Commission Regulation (EC) No 1508/1999 of 9 July 1999 amending Regulation (EC) No 1223/98 increasing to 567 036 tonnes the quantity of rye from harvests prior to 1997 held by the German intervention agency for which a standing invitation to tender for export has been opened . ..................................................... 25 Commission Regulation (EC) No 1509/1999 of 9 July 1999 amending Regulation (EC) No 1232/1999 increasing to 350 185 tonnes the quantity of wheat of breadmaking quality held by the German intervention agency for which a standing invitation to tender for export has been opened ................................................ 27 Price: EUR 19,50 (Continued overleaf) Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally EN valid for a limited period. The titles of all other acts are printed in bold type and preceded by an asterisk. Contents (continued) Commission Regulation (EC) No 1510/1999 of 9 July 1999 amending Regulation (EC) No 2198/98 increasing to 1 600 325 tonnes the quantity of barley held by the German intervention agency for which a standing invitation to tender for export has been opened ......................................................................... 29 = Commission Regulation (EC) No 1511/1999 of 9 July 1999 amending Regulation (EC) No 1261/96 establishing the forecast supply balance for the Canary Islands as regards wine products qualifying under the specific arrangements provided for in Articles 2 to 5 of Council Regulation (EEC) No 1601/92 ....................... 31 = Commission Regulation (EC) No 1512/1999 of 9 July 1999 on the issuing of import licences for bananas under the tariff quotas and for traditional ACP bananas for the third quarter of 1999 (second period) (1) ........................ 34 = Commission Regulation (EC) No 1513/1999 of 9 July 1999 setting for the 1999/ 2000 marketing year the minimum price and the amount of production aid for processed tomato products ..................................................... 35 = Commission Regulation (EC) No 1514/1999 of 9 July 1999 fixing for the 1999/ 2000 marketing year the minimum price to be paid to producers for dried plums and the amount of production aid for prunes ................................... 38 = Commission Directive 1999/64/EC of 23 June 1999 amending Directive 90/ 388/EEC in order to ensure that telecommunications networks and cable TV networks owned by a single operator are separate legal entities (1) .............. 39 = Council Directive 1999/70/EC of 28 June 1999 concerning the framework agree- ment on fixed-term work concluded by ETUC, UNICE and CEEP ................ 43 II Acts whose publication is not obligatory Council and Commission 1999/445/EC ECSC: = Council and Commission Decision of 29 April 1999 concerning the conclusion of the Agreement between the European Communities and the Government of Canada regarding the application of their competition laws ...................... 49 Agreement between the European Communities and the Government of Canada regarding the application of their competition laws ............................................ 50 Information on application between the European Community and Canada of the Agree- ment on international humane trapping standards between the European Community, Canada and the Russian Federation ................................................. 61 Information concerning the date of entry into force of the Interregional Framework Cooperation Agreement between the European Community and its Member States, of the one part, and the Southern Common Market and its Party States, of the other part ........ 62 EN (1) Text with EEA relevance (Continued on inside back cover) Contents (continued) Commission 1999/446/EC: = Commission Decision of 14 June 1999 amending Decision 98/131/EC approving the multi-annual guidance programme for the fishing fleet of Sweden for the period from 1 January 1997 to 31 December 2001 (notified under document number C(1999) 1531) .................................................................. 63 1999/447/EC: = Commission Decision of 14 June 1999 amending Decision 98/122/EC approving the multi-annual guidance programme for the fishing fleet of Germany for the period from 1 January 1997 to 31 December 2001 (notified under document number C(1999) 1533) .................................................................. 66 1999/448/EC: = Commission Decision of 14 June 1999 amending Decision 98/130/EC approving the multiannual guidance programme for the fishing fleet of Finland for the period from 1 January 1997 to 31 December 2001 (notified under document number C(1999) 1534) .................................................................. 68 1999/449/EC: = Commission Decision of 9 July 1999 on protective measures with regard to contamination by dioxins of certain products of animal origin intended for human or animal consumption (1) (notified under document number C(1999) 2110) ..... 70 Corrigenda = Corrigendum to Commission Directive 98/82/EC of 27 October 1998 amending the Annexes to Council Directives 86/362/EEC, 86/363/EEC and 90/642/EEC on the fixing of maximum levels for pesticide residue in and on cereals, foodstuffs of animal origin and certain prod- ucts of plant origin, including fruit and vegetables respectively (OJ L 290 of 29.10.1998) .... 83 EN (1) Text with EEA relevance 10. 7. 1999 EN Official Journal of the European Communities L 175/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1502/1999 of 9 July 1999 establishing the standard import values for determining the entry price of certain fruit and vegetables THE COMMISSION OF THE EUROPEAN COMMUNITIES, (2) Whereas, in compliance with the above criteria, the standard import values must be fixed at the levels set Having regard to the Treaty establishing the European out in the Annex to this Regulation, Community, Having regard to Commission Regulation (EC) No 3223/94 of 21 December 1994 on detailed rules for the application of the HAS ADOPTED THIS REGULATION: import arrangements for fruit and vegetables (1), as last amended by Regulation (EC) No 1498/98 (2), and in particular Article 1 Article 4 (1) thereof, The standard import values referred to in Article 4 of Regula- (1) Whereas Regulation (EC) No 3223/94 lays down, tion (EC) No 3223/94 shall be fixed as indicated in the Annex pursuant to the outcome of the Uruguay Round multi- hereto. lateral trade negotiations, the criteria whereby the Commission fixes the standard values for imports from Article 2 third countries, in respect of the products and periods stipulated in the Annex thereto; This Regulation shall enter into force on 10 July 1999. This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 9 July 1999. For the Commission Franz FISCHLER Member of the Commission (1) OJ L 337, 24.12.1994, p. 66. (2) OJ L 198, 15.7.1998, p. 4. L 175/2 EN Official Journal of the European Communities 10. 7. 1999 ANNEX to the Commission Regulation of 9 July 1999 establishing the standard import values for determining the entry price of certain fruit and vegetables (EUR/100 kg) Third country Standard import CN code code (1) value 0707 00 05 052 61,9 628 130,8 999 96,4 0709 90 70 052 53,6 999 53,6 0805 30 10 382 54,2 388 67,4 524 44,8 528 61,8 999 57,1 0808 10 20, 0808 10 50, 0808 10 90 388 84,0 400 79,1 508 78,4 512 72,3 524 58,7 528 74,2 804 101,0 999 78,2 0808 20 50 388 89,7 512 48,2 528 68,3 999 68,7 0809 10 00 052 132,01 064 74,6 999 103,4 0809 20 95 052 194,4 064 96,9 066 120,3 068 90,6 400 176,7 616 186,2 999 144,2 0809 40 05 624 258,0 999 258,0 (1) Country nomenclature as fixed by Commission Regulation (EC) No 2317/97 (OJ L 321, 22.11.1997, p. 19). Code ‘999’ stands for ‘of other origin’. 10. 7. 1999 EN Official Journal of the European Communities L 175/3 COMMISSION REGULATION (EC) No 1503/1999 of 9 July 1999 on issuing A2 export licences for fruit and vegetables THE COMMISSION OF THE EUROPEAN COMMUNITIES, (4) Whereas, pursuant to Article 3(5) of Regulation (EC) No 2190/96, applications for rates in excess of the cor- Having regard to the Treaty establishing the European responding definitive rates shall be considered null and Community, void, Having regard to Commission Regulation (EC) No 2190/96 of 14 November 1996 on detailed rules for implementing Council Regulation (EC) No 2200/96 as regards export refunds on fruit HAS ADOPTED THIS REGULATION: and vegetables (1), as last amended by Regulation (EC) No 1303/1999 (2), and in particular Article 3(4) thereof, Article 1 (1) Whereas Commission Regulation (EC) No 1304/ 1999 (3), as amended by Regulation (EC) No 1380/ 1.
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • E30 SEM. O.C. Disclosed Is a Compound Represented by the Formula (1) (51) Int
    USOO9453000B2 (12) United States Patent (10) Patent No.: US 9.453,000 B2 Kimura et al. (45) Date of Patent: *Sep. 27, 2016 (54) POLYCYCLIC COMPOUND (56) References Cited (75) Inventors: Teiji Kimura, Tsukuba (JP); Noritaka U.S. PATENT DOCUMENTS Kitazawa, Tsukuba (JP); Toshihiko 3,470,167 A 9, 1969 Sarkar Kaneko, Tsukuba (JP); Nobuaki Sato, 3,989,816 A 1 1/1976 Rajadhyaksha Tsukuba (JP); Koki Kawano, Tsukuba 4,910,200 A 3, 1990 Curtze et al. (JP): Koichi Ito, Tsukuba (JP); 5,281,626 A 1/1994 Oinuma et al. M s Tak ishi Tsukub JP 5,563,162 A 10, 1996 Oku et al. amoru Takaishi Tsukuba (JP); 5,804,577 A 9, 1998 Hebeisen et al. Takeo Sasaki, Tsukuba (JP); Yu 5,985,856 A 11/1999 Stella et al. Yoshida, Tsukuba (JP); Toshiyuki 6,235,728 B1 5, 2001 Golik et al. Uemura, Tsukuba (JP); Takashi Doko, g R 1939. E. al. Its SE E. Shinmyo, 7,138.414 B2 11/2006 Schoenafingereatch et al. et al. sukuba (JP); Daiju Hasegawa, 7,300,936 B2 11/2007 Parker et al. Tsukuba (JP); Takehiko Miyagawa, 7,314,940 B2 1/2008 Graczyk et al. Hatfield (GB); Hiroaki Hagiwara, 7,618,960 B2 11/2009 Kimura et al. Tsukuba (JP) 7,667,041 B2 2/2010 Kimura et al. 7,687,640 B2 3/2010 Kimura et al. 7,713,993 B2 5/2010 Kimura et al. (73) Assignee: EISAI R&D MANAGEMENT CO., 7,737,141 B2 6/2010 Kimura et al. LTD., Tokyo (JP) 7,880,009 B2 2/2011 Kimura et al.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Wo 2007/128674 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 15 November 2007 (15.11.2007) PCT WO 2007/128674 A2 (51) International Patent Classification: Houtenlaan 36, NL-1381 CP Weesp (NL). KRUSE, Cor- A61K 31/00 (2006.01) A61K 31/551 (2006.01) nelis G. [NL/NL]; c/o SOLVAY PHARMACEUTICALS A61K 31/439 (2006.01) A61P 25/18 (2006.01) B.V., IPSI Department, CJ. Van Houtenlaan 36, NL-1381 A61K 31/4439 (2006.01) CP Weesp (NL). (21) International Application Number: (74) Agent: VERHAGE, Marinus; Octrooibureau Zoan B.V., PCT/EP2007/053934 NL-1380 AC Weesp (NL). (22) International Filing Date: 23 April 2007 (23.04.2007) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (25) Filing Language: English CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, (26) Publication Language: English IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, (30) Priority Data: MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 061 13476.3 4 May 2006 (04.05.2006) EP RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, 60/797,355 4 May 2006 (04.05.2006) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (71) Applicant (for all designated States except US): SOLVAY (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS B.V.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Alzheimer's Disease Clinical Trials
    Clinical Trial Perspective 5 Clinical Trial Perspective Alzheimer’s disease clinical trials: past failures and future opportunities Clin. Invest. (Lond.) Over a decade has elapsed since the US FDA has approved a medication for Alzheimer’s Roy Yaari*,1,2 & Ann Hake1,2 disease (AD) despite clinical trials of numerous agents over a wide array of mechanisms 1Eli Lilly & Company, Lilly Corporate including neurotransmitter modulation and disease modifying therapy targeting Center, Indianapolis, IN 46285, USA 2Indiana University School of Medicine, amyloid and tau. The failures of clinical trials in AD may be due to inadequate Department of Neurology, Indianapolis, understanding of mechanisms of action and/or poor target engagement; however, IN 46202, USA other factors could include inadequate study design, stage of AD along the continuum *Author for correspondence: studied, inclusion of participants without Alzheimer’s pathology into clinical trials Tel.: +1 317 651 6163 and limited power of endpoint measures. Future studies will need to carefully assess [email protected] these possible shortcomings in design of upcoming trials, especially as the field moves toward studies of disease modifying agents (as opposed to symptomatic treatment) of AD and to patients that are very early in the disease spectrum. Keywords: Alzheimer’s disease • Alzheimer’s disease biomarkers • amyloid • clinical trials • preclinical Alzheimer’s disease • tau US FDA approved medications continue to provide significant, but modest More than three decades ago, the choliner- symptomatic benefit[5–7] . gic hypothesis proposed that degeneration The compound memantine introduced a of cholinergic neurons in the basal fore- second mechanism for symptomatic treat- brain and the associated loss of cholinergic ment of AD into clinical practice.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski Et Al
    US009687458B2 (12) United States Patent (10) Patent No.: US 9,687,458 B2 Podolski et al. (45) Date of Patent: Jun. 27, 2017 (54) TRANS-CLOMIPHENE FOR USE IN 6,143,353 A 1 1/2000 Oshlack CANCER THERAPY 6,190,591 B1 2/2001 Van Lengerich 6,221,399 B1 4/2001 Rolfes 6,248,363 B1 6, 2001 Patel (71) Applicant: REPROS THERAPEUTICS INC., 6,291,505 B1 9/2001 Huebner et al. The Woodlands, TX (US) 6,342,250 B1 1/2002 Masters 6,391920 B1 5, 2002 Fisch (72) Inventors: Joseph S. Podolski. The Woodlands, 6,511.986 B2 1/2003 Zhang et al. TX (US); Ronald D. Wiehle, Houston, 826 R $398 Ma'al TX (US); Kuang Hsu, The Woodlands, 6,638,528s- ww. B1 10/2003 KaniosaO ( a. TX (US); Greg Fontenot, The 6,645,974 B2 11/2003 Hutchinson et al. Woodlands, TX (US) 6,653,297 B1 11/2003 Hodgen 6,685,957 B1 2/2004 Bezemer et al. (73) Assignee: Repros Therapeutics Inc., The $33. R: 3. ErSC Woodlands, TX (US) 7,105,679 B2 9/2006 Kanojia et al. 7,354,581 B2 4/2008 Cedarb tal. (*) Notice: Subject to any disclaimer, the term of this 7,799,782 B2 9/2010 T al patent is extended or adjusted under 35 8,247456 B2 8/2012 Podolski U.S.C. 154(b) by 0 days. 8,377,991 B2 2/2013 Van AS 2002/O1200 12 A1 8, 2002 Fisch (21) Appl. No.: 14/440,007 (Continued) (22) PCT Filed: Oct.
    [Show full text]
  • Preparation, Characterization, and in Vitro Enzymatic Hydrolysis in Biorelevant Media☆
    European Journal of Pharmaceutical Sciences 92 (2016) 203–211 Contents lists available at ScienceDirect European Journal of Pharmaceutical Sciences journal homepage: www.elsevier.com/locate/ejps Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media☆ Vikas Kumar a,b, Sonali S. Bharate a,⁎, Ram A. Vishwakarma b,c,⁎⁎ a Preformulation Laboratory, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India b Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India c Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India article info abstract Article history: Rohitukine is a medicinally important natural product which has inspired the discovery of two anticancer clinical Received 26 May 2016 candidates. Rohitukine is highly hydrophilic in nature which hampers its oral bioavailability. Thus, herein our ob- Received in revised form 27 June 2016 jective was to improve the drug-like properties of rohitukine via prodrug-strategy. Various ester prodrugs were Accepted 11 July 2016 synthesized and studied for solubility, lipophilicity, chemical stability and enzymatic hydrolysis in plasma/ester- Available online 12 July 2016 ase. All prodrugs displayed lower aqueous solubility and improved lipophilicity compared with rohitukine, which was in accordance with the criteria of compounds in drug-discovery. The stability of synthesized prodrugs was Keywords: Prodrugs evaluated in buffers at different pH, SGF, SIF, rat plasma and in esterase enzyme. The rate of hydrolysis in all in- Drug discovery cubation media was dependent primarily on the acyl promoieties. Hexanoyl ester prodrug of rohitukine, 3d,was Rohitukine stable under chemical conditions; however it was completely hydrolyzed to rohitukine, in plasma and in esterase Solubility in 4 h.
    [Show full text]
  • Effect of Estrogens on Skin Aging and the Potential Role of Selective Estrogen Receptor Modulators
    CLIMACTERIC 2007;10:289–297 Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators S. Verdier-Se´vrain Bio-Hybrid, LLC, West Palm Beach, Florida, USA Key words: SKIN AGING, HORMONE REPLACEMENT THERAPY, TOPICAL ESTROGEN, PHYTOESTROGENS, SELECTIVE ESTROGEN RECEPTOR MODULATORS ABSTRACT Estrogens have a profound influence on skin. The relative hypoestrogenism that accom- panies menopause exacerbates the deleterious effects of both intrinsic and environ- mental aging. Estrogens prevent skin aging. They increase skin thickness and improve skin moisture. Beneficial effects of hormone replacement therapy (HRT) on skin aging have been well documented, but HRT cannot obviously be recommended solely to treat skin aging in menopausal women. Topical estrogen application is highly effective and safe if used by a dermatologist with expertise in endocrinology. The question of whether estrogen alternatives such as phytoestrogens and selective estrogen receptor modulators are effective estrogens for the prevention of skin aging in postmenopausal women remains unanswered. However, preliminary data indicate that such treatment may be of benefit for skin aging treatment. For personal use only. INTRODUCTION There are approximately 40 million postmeno- Intrinsic aging is characterized by smooth, pale, pausal women in the United States, contributing finely wrinkled skin and dryness2. Photoaging is to 17% of the total population1. As the popula- characterized by severe wrinkling and pigmentary tion of older women continues to grow at a rapid changes such as solar lentigo and mottled pig- rate, the challenges of learning more about the mentation3. Estrogens affect several skin functions health-care concerns and priorities of this group of and the estrogen deprivation that accompanies Climacteric Downloaded from informahealthcare.com by University of Washington on 05/23/13 patients become apparent.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]